• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

PDABs and the IRA: The Impact of Federal Legislation on State-Level Prescription Pricing Practices

Wednesday, June 05, 2024
Breakout Session
Value‚ Patient Access and Reimbursement
23BC
Uncertainties exist around American drug pricing policy, and as the U.S. government moves ahead with implementation of the Inflation Reduction Act (IRA), state legislatures are increasingly considering Prescription Drug Affordability Boards (PDABs) to lower prescription drug costs. Eight states have enacted PDABs, and it’s speculated more states will adopt similar policies to expand oversight of state-regulated markets and mechanisms to address pricing. As the IRA moves into the implementation phase – barring any significant modifications – stakeholders are identifying consequences that threaten patients’ access to medicines and disrupt the innovation incentives for manufacturers. This panel will feature policy experts offering perspectives on state-level PDABs in a post IRA-world, how these regulatory bodies affect accessibility and affordability of prescription drugs for patients, and what can be done to ensure patient access to innovative new treatments continues.
Moderator
Elizabeth (Liz) Helms
President and CEO
California Chronic Care Coalition
Speakers
John O’Brien, PharmD, MPH
President and CEO
National Pharmaceutical Council
Christopher (Brett) Johnson, JD
Director, State Government Affairs
Amgen
John Murphy
Chief Policy Officer
Biotechnology Innovation Organization (BIO)
Tiffany Westrich-Robertson
Chief Executive Officer and Co-Founder
AiArthritis
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS